Akaal Tech & Agro and Hb-22 collaborate on the novel human and tertiary formulation development.
02/03/2022

Akaal Tech and Agro Pty Ltd (ATA) and Hb-22 today announced a collaboration to develop novel formulations including cannabidiol (CBD) and novel patented NSAIDs.

Online PR News – 03-February-2022 – Lemnos, Shepparton, VIC, AUS – Akaal Tech and Agro Pty Ltd (ATA) and Hb-22 today announced a collaboration to develop novel formulations including cannabidiol (CBD) and novel patented NSAIDs. The collective approach is to take to the clinic human and veterinary drug products for life saving diseases.

Hb-22 has proprietary formulation technology and ATA has gained right to develop library of small molecules as anti-inflammatory entities. 'Initial data of using Hb-22 formulations shows promising potential for solving some of the central problems in CBD pharmacology' said Mr. Ram, Director of Hb-22. ‘The combinations of active small molecules and CBD through regulated path of preclinical and clinical development in difficult to treat indications would be our priority said Dr. Gurmit Gill co-founder of ATA, and inventor of patented NSAIDs.

ATA is an Australia based biotech company and have acquired rights to develop NCE small anti-inflammatory molecules into human and veterinary medications. Hb-22 is a US based company that develops novel formulations altering bioavailability and release patterns.

For further information contact gautam@akaaltechagro.com